Results 201 to 210 of about 35,241 (222)

Progress in precision therapies for advanced cholangiocarcinoma: inhibitors of FGFR1-3. [PDF]

J Gastrointest Oncol
Wadsley J.
europepmc   +1 more source

Second-Line Treatment in cholangiocarcinoma - Current State of the Art and Future Perspectives. [PDF]

Curr Treat Options Oncol
Siwek M, Chmiel P, Grabowska H, Grąt M, Kraj L.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.

Journal of Clinical Oncology, 2023
4009 Background: Oncogenic FGFR2 alterations (fusions/rearrangements (f/r), amplifications, mutations) represent a broad therapeutic opportunity as they drive multiple solid tumors, particularly cholangiocarcinoma (CCA). However, off-isoform toxicity and
M. Borad, A. Schram, R. Kim, Suneel D. Kamath, V. Sahai, E. Dotan, R. Kelley, M. Ponz-Sarvisé, D. Oh, J. Yachnin, V. Florou, P. Cassier, Joon-Oh Park, C. Liao, Michael Millward, F. T. Ramirez, F. Ricard, A. Hollebecque, V. Subbiah, L. Goyal   +19 more
semanticscholar   +1 more source

Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer.

Journal of Medicinal Chemistry, 2023
Abnormal activation of fibroblast growth factor receptors (FGFRs) results in the development and progression of human cancers. FGFR2 is frequently amplified or mutated in cancers; therefore, it is an attractive target for tumor therapy.
Lin Ma, Yingying Li, Ruixiang Luo, Yuhan Wang, Jiaqi Cao, Weitao Fu, Bolan Qian, Lei Zheng, Longguang Tang, Xinting Lv, Lulu Zheng, Guang Liang, Lingfeng Chen   +12 more
semanticscholar   +1 more source

Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.

Journal of Clinical Oncology, 2022
4009 Background: Survival outcomes are historically poor in patients (pts) with advanced/metastatic iCCA, with median overall survival (mOS) times of approximately 1 year with first-line gemcitabine plus cisplatin and approximately 6 months with second ...
L. Goyal, F. Meric-Bernstam, A. Hollebecque, C. Morizane, J. Valle, T. Karasic, T. Abrams, R. Kelley, P. Cassier, J. Furuse, H. Klümpen, H. Chang, Li‐Tzong Chen, Y. Komatsu, K. Masuda, D. Ahn, Kate Li, K. Benhadji, V. Wacheck, J. Bridgewater   +19 more
semanticscholar   +1 more source

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

, 2021
265Background: Treatment options for cholangiocarcinoma (CCA) after progression on first-line gemcitabine-based therapy are limited.
M. Javle, S. Roychowdhury, R. Kelley, S. Sadeghi, T. Macarulla, D. Waldschmidt, L. Goyal, I. Borbath, A. El-Khoueiry, Weipeng Yong, P. Philip, M. Bitzer, S. Tanasanvimon, Ai Li, A. Pande, S. Shepherd, S. Moran, G. Abou-Alfa   +17 more
semanticscholar   +1 more source

FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations

Digestive Diseases and Sciences, 2021
FGFR2 genomic alterations are observed in 10-20% of cholangiocarcinoma (CCA). Although FGFR2 fusions are an important actionable target, FGFR2 protein expression has not been thoroughly characterized.To evaluate FGFR2 protein expression in cholangiocarcinoma harboring FGFR2 genomic alterations.FGFR2 protein expression was evaluated in 99 CCA cases with
Pedro Luiz Serrano Uson Junior, Thomas T. DeLeon, James M. Bogenberger, Rish K. Pai, Heidi E. Kosiorek, Jun Yin, Daniel H. Ahn, Mohammad Bassam Sonbol, Tanios Bekaii-Saab, Aaron S. Mansfield, Kenneth Buetow, Gregory J. Gores, Rory Smoot, George Vasmatzis, Benjamin R. Kipp, Amit Mahipal, Alexander T. Baker, Hani Babiker, Oumar Barro, Chelsae Dumbauld, Yumei Zhou, Faaiq N. Aslam, Michael Barrett, Bertram Jacobs, Nathalie Meurice, Mansi Arora, Joachim Petit, Natalie Elliott, Bolni Nagalo, Marcela A. Salomao, Mitesh J. Borad   +30 more
openaire   +2 more sources

A novel mutation in FGFR2

American Journal of Medical Genetics Part A, 2014
Craniosynostosis is a congenital anomaly that can occur as an isolated condition or as part of a syndrome. Although several genes are known to cause syndromic craniosynostosis, only 24% can be attributed to known genes. Therefore, it is likely that more mutations and other genes are involved.
Goos, Jacqueline, van den Ouweland, Ans, Swagemakers, Sigrid, Verkerk, Annemieke, Hoogeboom, Jeannette, van Veelen - Vincent, M.L.C., Mathijssen, Irene, van der Spek, Peter   +7 more
openaire   +3 more sources

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.

Future Oncology, 2020
Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately 15% of intrahepatic cholangiocarcinomas contain FGFR alterations. Infigratinib is an oral FGFR 1-3 kinase inhibitor.
S. Makawita, Ghassan K Abou-Alfa, S. Roychowdhury, S. Sadeghi, I. Borbath, L. Goyal, A. Cohn, A. Lamarca, D. Oh, T. Macarulla, Rachna T Shroff, M. Howland, Ai Li, T. Cho, A. Pande, M. Javle   +15 more
semanticscholar   +1 more source